Different forms of alpha-1 antitrypsin and neutrophil activation mediated by human anti-PR3 IgG antibodies.
BACKGROUND
One of characteristic findings in granulomatosis with polyangiitis (GPA) is the presence of proteinase-3 (anti-PR3) specific antibodies. These antibodies can cause neutrophil activation, degranulation and generation of reactive oxygen species (ROS). Each of these inflammatory events can be suppressed by circulating alpha-1 antitrypsin (A1AT). A1AT is an acute phase protein increasing during inflammation, however, it may circulate as an inactive polymeric protein. The aim was to analyze how different types of A1AT can affect anti-PR3 mediated neutrophil activation.


METHODS
Granulocytes were obtained from the blood of healthy volunteers and purified by density gradient centrifugation. Effects of A1AT on IgG anti-PR3-mediated neutrophil activation were evaluated by stimulation of the cells with native IgG anti-PR3 antibodies in the presence of native or polymerized A1AT. Analyses of selected proinflammatory genes expression were performed using quantitative real-time. Flow cytometry was used to study the cell membrane PR3, its binding by anti-PR3 IgG, and production of ROS at presence A1AT. Neutrophil elastase complexes with A1AT were measured by ELISA.


RESULTS
Native A1AT inhibited formation of the immune complex of PR3 with anti-PR3 and anti-PR3-mediated neutrophil activation/ROS production. Protective effect of polymerized A1AT against these events was diminished at least fivefold.


CONCLUSIONS
Native A1AT can prevent pivotal events of neutrophils' activation by anti-PR3 IgG, the main autoantibody in anti-PR3 dependent vasculitis. Inhibitory properties of polymerized A1AT, decreased plausibly due to a loss of anti-protease function, can explain more severe course of the disease in subjects with deficiency of A1AT.
Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland.
Marcin
M
Surmiak
Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland. Electronic address: nfsanak@cyf-kr.edu.pl.
Marek
M
Sanak
D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis*; D008297:Male; D053146:Myeloblastin / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D000515:alpha 1-Antitrypsin / Q000737:chemistry / Q000494:pharmacology*
D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; C043392:SERPINA1 protein, human; D000515:alpha 1-Antitrypsin; D053146:Myeloblastin
Alpha-1 antitrypsin; Cytoplasmic anti-neutrophil cytoplasm antibodies; Granulomatosis with polyangiitis; Neutrophil activation; Proinflammatory genes expression